Femasys to showcase FemBloc, other products at AAGL meeting

Femasys will highlight its product candidate in late stage clinical development, FemBloc, as well as showcase three of its marketed products advancing women’s health, FemVue, FemCath and FemCerv, at the annual meeting of the American Association of Gynecologic Laparoscopic Surgeons being held in Nashville, Tennessee from November 5-8, 2023. The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures. Femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, FemBloc in late-stage clinical development for permanent birth control and its United States Food and Drug Administration cleared product, FemaSeed for infertility treatment that is also approved in Canada. The Company is also commercializing complementary diagnostic products, FemVue, FemCath and FemCerv, all of which were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada and other ex-U.S. territories.